A detailed history of Bard Financial Services, Inc. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Bard Financial Services, Inc. holds 15,000 shares of IBRX stock, worth $76,800. This represents 0.01% of its overall portfolio holdings.

Number of Shares
15,000
Previous 15,000 -0.0%
Holding current value
$76,800
Previous $55,000 -0.0%
% of portfolio
0.01%
Previous 0.01%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$3.23 - $6.17 $13,727 - $26,222
-4,250 Reduced 22.08%
15,000 $80,000
Q2 2023

Jul 11, 2023

BUY
$1.53 - $6.41 $29,452 - $123,392
19,250 New
19,250 $53,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $2.05B
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Bard Financial Services, Inc. Portfolio

Follow Bard Financial Services, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bard Financial Services, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bard Financial Services, Inc. with notifications on news.